The trial named EORTC 75111- 10,114 enrolled eighty patients diagnosed with metastatic HER2+ BC and were treated with a metronomic oral CTX (50 mg Qd) and dual anti-HER2 agents (trastuzumab + pertuzumab) as first-line therapy. Here, ERBB2 is linked to breast cancer.